<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0001342'>Intracerebral hemorrhage</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>) accounts for a majority of long-term morbidity and mortality associated with <z:mp ids='MP_0001914'>bleeding</z:mp> while on <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and <z:chebi fb="8" ids="10033">warfarin</z:chebi>-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> appear to have a genetic component </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, advanced neuroimaging using MRI can now identify individuals at increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We explore whether screening strategies that include genetic profiling and neuroimaging might improve the safety of <z:hpo ids='HP_0011010'>chronic</z:hpo> anticoagulation for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> by identifying individuals from whom <z:chebi fb="8" ids="10033">warfarin</z:chebi> should be withheld </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We used a Markov state transition decision model </plain></SENT>
<SENT sid="5" pm="."><plain>Effectiveness was measured in quality-adjusted life-years </plain></SENT>
<SENT sid="6" pm="."><plain>Data sources included the English language literature using MEDLINE searches and bibliographies from selected articles along with empirical data from our institutions </plain></SENT>
<SENT sid="7" pm="."><plain>The base case was a 69-year-old man with newly diagnosed nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: For patients at average risk for <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> and known to possess a hypothetical genetic profile increasing risk for <z:chebi fb="8" ids="10033">warfarin</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>, anticoagulation remains the preferred strategy until the relative hazard of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> exceeds 23.8 </plain></SENT>
<SENT sid="9" pm="."><plain>Genetic profiling would be favored for patients at low risk of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (1.5% per year) if the hypothetical gene variant(s) conferred a relative risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> &gt;4.1 </plain></SENT>
<SENT sid="10" pm="."><plain>Screening strategies in which patients underwent genotyping and MRI before anticoagulation did not improve aggregate patient outcomes unless the predictive power of MRI exceeded current best guess estimates and patients were at low to moderate risk of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Currently identified genetic markers of <z:mp ids='MP_0001914'>bleeding</z:mp> risk do not confer a risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> sufficiently high to warrant routine genetic testing for patients at average risk of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Even if patients undergo screening with MRI as well as genotyping, currently available data on the role of MRI on risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> and <z:chebi fb="8" ids="10033">warfarin</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> do not support use of these tests for withholding anticoagulation in patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
</text></document>